Mutations in the amyloid precursor protein (APP) gene cause early-onset familial Alzheimer
disease (AD) by affecting the formation of the amyloid β (Aβ) peptide, the major constituent …

Protein aggregation is an established pathogenic mechanism in Alzheimer's disease, but little
is known about the initiation of this process in vivo. Intracerebral injection of dilute, amyloid…

Abstract Machine rule induction was examined on a difficult categorization problem by
applying a Holland-style classifier system to a complex letter recognition task. A set of 20,000 …

As Alzheimer's disease pathogenesis is associated with the formation of insoluble aggregates
of amyloid β-peptide, approaches allowing the direct, noninvasive visualization of plaque …

Graft polymerization of acrylic acid onto plasma treated poly(ethylene terephthalate) (PET)
films was carried out to develop surfaces for protein immobilization and smooth muscle cell …

The use of simulations and digital games in learning and assessment is expected to increase
over the next several years. Although there is much theoretical support for the benefits of …

The progressive deposition of the amyloid β peptide (Aβ) in fibrillar form is a key feature in
the development of the pathology in Alzheimer's disease (AD). We have characterized the …

The amyloid β-protein transiently forms low and high molecular mass oligomers and protofibrils
in vitro, and after longer incubation times assembles into polymorphic mature fibrils. The …

Immunization against amyloid-β (Aβ) can reduce amyloid accumulation in vivo and is
considered a potential therapeutic approach for Alzheimer's disease. However, it has been …

Objective To investigate whether symptomatic treatment with non-steroidal anti-inflammatory
drugs (NSAIDs) is non-inferior to antibiotics in the treatment of uncomplicated lower urinary …